J&J Settles Talc Cancer Claims for $5.5 Billion

Women who used Johnson & Johnson talc products for decades now stand to receive compensation through a proposed $5.5 billion settlement covering roughly 76,000 ovarian cancer claims. The agreement, announced July 28, resolves nearly all remaining lawsuits consolidated in federal court in New Jersey and scattered state courts. It does not cover future claims or the separate mesothelioma cases already settled by the company.

The deal requires approval from 95 percent of the ovarian cancer claimants before it becomes binding. Johnson & Johnson expects to pay $3 billion in 2027 and additional amounts in 2028, though the total could rise above $5.5 billion if participation exceeds minimum thresholds. Plaintiffs' attorney Chris Seeger, who represents about 2,500 clients and helped negotiate the terms, said the structure assigns specific values to qualifying claims without an overall cap.

Johnson & Johnson vice president of litigation Erik Haas called the claims meritless yet described the settlement as a path to closure. "While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it," Haas said. Seeger countered that the outcome delivers a fair result after ten years of litigation.

The settlement follows courtroom successes for the company, including a recent federal magistrate order questioning plaintiffs' ability to prove specific causation. Earlier, Johnson & Johnson won individual trials, disqualified some plaintiffs' counsel, and obtained rulings limiting expert testimony. The company stopped selling talc-based baby powder in the United States in 2020 and switched to a cornstarch formula.

Litigation had been paused for more than three years while Johnson & Johnson attempted a bankruptcy strategy through a subsidiary, known as the Texas two-step. Those filings were dismissed. Before the bankruptcy efforts, the company faced a mixed trial record that included a multibillion-dollar verdict for 22 women later reduced on appeal. One outlet reported prior payouts of $2.5 billion in Missouri in 2021 and $700 million to resolve a 2024 multistate attorneys general investigation; those figures could not be independently verified by other outlets. The International Agency for Research on Cancer classification of talc as probably carcinogenic to humans, referenced in one analysis, also lacks corroboration across the coverage examined.